Skip to content

Search

Showing results for "mental health aboriginal"

Our team

Our team of world-class researchers and exceptional clinicians work in collaboration to provide children access to the very best evidence-based therapies and programs.

Looking at autism through a social model

In​ this blog, Speech Pathologist Linda Arabi discusses the social model and how it influences the supports we provide to autistic children and their families.

Confident and Trustworthy Model for Fidgety Movement Classification

General movements (GMs) are part of the spontaneous movement repertoire and are present from early fetal life onwards up to age five months. GMs are connected to infants' neurological development and can be qualitatively assessed via the General Movement Assessment. In particular, between the age of three to five months, typically developing infants produce fidgety movements and their absence provides strong evidence for the presence of cerebral palsy.

Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network

Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network.

Invasive pneumococcal disease in children with acute lymphoblastic leukaemia

To determine the incidence, serotype distribution and clinical outcomes of invasive pneumococcal disease in children with acute lymphoblastic leukaemia following widespread use of pneumococcal conjugate vaccines.

Clinical Predictors of Longitudinal Respiratory Exacerbation Outcomes in Young Hospitalised Children

Respiratory infection and wheezing illness are leading causes of hospitalisation in childhood, placing a significant burden on families and healthcare systems. However, reliably distinguishing children at risk of developing persistent disease from those likely to outgrow their symptoms remains a clinical challenge. Earlier identification would allow clinicians to focus care and resources on those most likely to benefit from long-term management, while reducing anxiety and uncertainty about the future for families.

Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study

Invasive fungal disease (IFD) is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML.

The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A crosssectional study

Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.

Neonatal and infant mortality after maternal influenza and pertussis vaccination: Probabilistically linked cohort study

Maternal influenza and pertussis vaccination is an important strategy to reduce morbidity and mortality in infants. Previous vaccine safety studies have mostly focused on the association between maternal vaccination and fetal death.

The mark of success: The role of vaccine-induced skin scar formation for BCG and smallpox vaccine-associated clinical benefits

Skin scar formation following Bacille Calmette-Guérin (BCG) or smallpox (Vaccinia) vaccination is an established marker of successful vaccination and 'vaccine take'. Potent pathogen-specific (tuberculosis; smallpox) and pathogen-agnostic (protection from diseases unrelated to the intentionally targeted pathogen) effects of BCG and smallpox vaccines hold significant translational potential.